Searching map area
Plasminogen (medication)
? TBD
Medication for hypoplasminogenemia
Join to rate
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
8
The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release
scholarly article
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
scientific article published on February 2004
Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1
scientific article published on 23 February 2005
Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non-intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions
scientific article published on 29 April 2010
Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity
scientific article published on 27 June 2006
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact
scientific article published on 02 July 2009
Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects
scientific article
Physiological consequences of loss of plasminogen activator gene function in mice
scientific article published in Nature
Lists
0
Join to rate

Plasminogen, sold under the brand name Ryplazim, is a biologic medication for the treatment of hypoplasminogenemia (plasminogen deficiency type 1). It is purified from human plasma and is administered intravenously.

Instance of
Medication
Wikidata